[No evidence of fewer influenza complications with oseltamivir].
Since August 7th, treatment with neuraminidase inhibitors (oseltamivir) in the Netherlands has been limited to those patient groups who are considered at high risk of influenza-related complications. This policy is based on one study which shows only limited evidence of the effectiveness of neuraminidase inhibitors in lowering the number of such complications.
Nederlands Interdisciplinair Demografisch Instituut (NIDI/KNAW), Den Haag, The Netherlands. bonneux@nidi.nl
Luc
L
Bonneux
D000998:Antiviral Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D053139:Oseltamivir / Q000627:therapeutic use*; D011292:Premedication
D000998:Antiviral Agents; D053139:Oseltamivir